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Background: Various treatment strategies for low-grade chondrosarcomas with variable outcomes have been
reported in the literature. The aim of this study was to assess the oncological and functional outcomes associated
with intralesional curettage followed by adjuvant therapy comprising high-speed burring, thermal cauterization, and
bone cementation with polymethylmethacrylate.
Methods: We performed a retrospective review of 21 consecutive patients with intramedullary low-grade
chondrosarcoma of long bones treated by intralesional curettage and adjuvant therapy comprising high-speed
burring, thermal cauterization, and cementation at our institution from 2007 to 2012.
Results: The average age of the patients was 48.7 (range, 18–71) years. There were 7 male and 14 female patients.
The mean follow-up period was 58.4 (range, 26–85) months after surgery. The treated lesions were located in the
proximal humerus (n =10), proximal tibia (n =6), and distal femur (n =5). At the average follow-up time point of
58.4 (range, 26–85) months, no patient had developed local recurrence and no distant metastases were observed.
The average Musculoskeletal Tumor Society score among all 21 patients was 95% (84–100).
Conclusions: The combination of intralesional curettage, application of high-speed burring, thermal cauterization,
and cementation is an effective treatment strategy for low-grade intramedullary chondrosarcoma of long bones.
Excellent oncological and functional results can be obtained.Background
Chondrosarcoma (CS) is the second most frequent
primary malignant bone tumor after osteosarcoma.
Central CS may grow primarily in the medullary canal
of healthy bone or may be secondary to pre-existing
benign enchondroma [1].
The prognosis of central CS is directly correlated with
the histological grade of malignancy, which is assessed
following the criteria described by Evans et al., which
consider the tumor’s cellularity, matrix characteristics,
nuclear features, and mitotic rate [2]. Histologic evalu-
ation of cartilaginous tumors represents a challenging
task for the pathologist, and consistent interobserver
variability in the tumor grade and distinction between* Correspondence: drugurmermerkaya@gmail.com
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article, unless otherwise stated.benign and malignant lesions has been observed [3,4].
The concept of the “borderline” lesion was introduced, in-
dicating a cartilaginous lesion more active than a benign
enchondroma but less atypical than a grade 1 CS [5].
The most important predictors of poor survival of pa-
tients with CS are a high histological grade and an age
of more than 50 years [6]. Surgery is the primary treat-
ment for cartilage tumors, and the extent of the resec-
tion margins depends on the tumor grade and location
[7,8]. Radiation therapy and chemotherapy have no sub-
stantial role in the treatment of CS [9-11].
Previously reported CS treatment results are difficult
to interpret because of differences in grading criteria,
combination with axial and appendicular tumors, and
various treatment combinations [12-15]. The aim of this
study is to determine the clinical outcomes of patients
with grade I CS of the appendicular long bones. All pa-
tients underwent one intralesional curettage procedurentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ring, thermal cauterization, and bone cementation with
polymethylmethacrylate.
Methods
We retrospectively evaluated 21 patients treated for grade
I central CS of a long bone in our hospital from 2007 to
2012 (Table 1). Patients from hospitals in the surrounding
areas who were suspected of having CS were referred to
our musculoskeletal oncology department.
All 21 consecutive patients with histologically verified
low-grade intramedullar CS of a long bone underwent
intralesional curettage and cementation of their lesion at
our institution. These patients were identified using our
department’s histopathology database and then reviewed
retrospectively. Surgery involved an oncologically safe biopsy
followed by intralesional curettage, high-speed burring, and
thermal cauterization. Cementation was performed immedi-
ately or 2 weeks later.
The inclusion criterion for this study was a histological
diagnosis of grade I central CS located in a long bone.
We excluded patients with lesions breaching the bone
cortex and/or associated with a soft tissue mass because
such lesions were treated by wide excision. The patients
included in this study underwent intralesional curettageTable 1 Summary of patient data




1 Female 18 Proximal tibia 68 96.5
2 Female 19 Proximal tibia 39 96.5
3 Male 35 Distal femur 41 96.5
4 Female 38 Proximal humerus 48 100
5 Male 41 Distal femur 55 96.5
6 Male 41 Proximal humerus 76 96.5
7 Female 47 Distal femur 85 93.2
8 Female 47 Proximal humerus 52 100
9 Female 49 Distal femur 26 96.5
10 Female 49 Proximal humerus 80 96.5
11 Male 50 Proximal tibia 42 89.9
12 Male 53 Proximal humerus 51 100
13 Female 53 Proximal humerus 78 100
14 Female 54 Proximal humerus 55 100
15 Female 54 Proximal tibia 51 93.2
16 Female 56 Proximal humerus 60 89.9
17 Male 56 Proximal tibia 52 96.5
18 Female 58 Distal femur 65 89.9
19 Female 65 Proximal humerus 81 83.2
20 Male 69 Proximal humerus 58 93.2
21 Female 71 Proximal tibia 64 86.5of their lesion through a cortical window, followed by
application of high-speed burring, thermal cauterization,
and bone cementation.
The resultant intraosseous defects were reconstructed
with polymethylmethacrylate bone cement because it pro-
vides immediate stability, avoids morbidity of the autogen-
ous bone graft, and aids the postoperative radiographic
evaluation for signs of local recurrence [16]. Patients were
admitted to the hospital for 1 to 3 days depending on the
site of CS. Postoperative management was dependent
upon the tumor site and bone window size. Patients with
a CS in the upper extremity were managed with a sling for
2 to 6 weeks postoperatively. Following curettage in the
lower extremities, patients were either non-weight-bearing
or partially weight-bearing for 6 weeks and used crutches
once they were mobile. None of the patients were treated
with internal fixation and casts were not necessary be-
cause of the less invasive and limited nature of our surgical
procedure compared with wide resection and reconstruc-
tion of the long bone.
Patients were followed by means of physical examination,
radiographs, and computed tomography (CT) or magnetic
resonance imaging of the extremity as well as CT of
the chest (to rule out lung metastasis) every 3 months for
the first 2 years, every 6 months from 2 to 5 years, andFigure 1 Radiographic findings in low grade chondrosarcoma
of proximal humerus. (a) A 55-year-old female patient with a
diagnosis of low-grade CS in the proximal humerus. (b,c) Coronaland
axial magnetic resonance images at diagnosis. (d) Plain radiography 5
years after surgery.
Figure 2 Radiographic findings in low grade chondrosarcoma
of distal femur. (a, b) A 52-year-old female patient with a low-grade
chondrosarcoma in the right distal femur. (c, d) Radiographs after
48 months from the surgery.
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formed using the Musculoskeletal Tumor Society (MSTS)
scoring system for the upper and lower limbs [17]. The
predictive factors evaluated included radiographic evidence
of endosteal scalloping, tumor size, soft tissue extension,
tumor location (long bones or axial skeleton), patient
age, cortical erosion on CT scans or radiographs, and the
presence of preoperative pain. The outcomes included the
MSTS score and tumor recurrence.Figure 3 Microscopic findings in low grade chondrosarcoma (H&E). (a
(b) Host bone permeation is a hallmark of chondrosarcoma.Results
Oncological outcome
The average age of patients was 48.7 (range, 18 to 71)
years. There were 7 male and 14 female patients. The
mean follow-up period was 58.4 (range, 26 to 85) months
after surgery. The treated lesions were located in the prox-
imal humerus (n =10), proximal tibia (n =6), and distal
femur (n =5). At the average follow-up time point of 58.4
(range, 26 to 85) months, no patient had developed local
recurrence and no distant metastases were identified.Histological findings
All patients were diagnosed with a grade I central CS ac-
cording to the recently published consensus criteria [3]
and the system described by Evans et al. [2] (Figures 1
and 2). Lobules composed of few chondrocytes within
abundant chondroid matrix are consistent with chon-
droid neoplasm, either enchondroma or low-grade chon-
drosarcoma (Figure 3a); however, the presence of host
bone permeation (Figure 3b) is diagnostic for low grade
(grade 1) chondrosarcoma.Complications
One patient developed a superficial wound infection post-
operatively, which was resolved with antibiotics.Functional outcome
The average MSTS score in all 21 patients was 95% (84%
to 100%). The mean upper limb score was 96% (83% to
100%), whereas the mean lower limb score was 94% (86%
to 96%). All patients were able to perform activities relat-
ing to their daily living and occupation. Two patients re-
ported episodes of mild pain around the operation site.) Hypocellular chondroid lobules on low power magnification.
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There is currently no universally accepted operative
treatment for low-grade CS of long bones. Intralesional
curettage, either alone or combined with local adjuvant
treatments, marginal resection, and en bloc resection
with biologic or endoprosthetic reconstruction are de-
scribed in the literature [18-20]. In contrast, high-grade
CS is almost always treated with wide excision achieved
by either amputation or resection of the tumor with
limb salvage reconstruction [6,12,14,21]. Wide resection
of these indolent, slow-growing, low-grade tumors seems
disproportionate in light of the difficulty in distinguishing
them from enchondromas [22,23] and the fact that wide
resection often results in substantial functional morbidity
[24,25]. Hickey et al. performed a meta-analysis involving
78 patients treated with intralesional resection and 112 pa-
tients treated with wide resection for grade I CS; no sig-
nificant differences in local recurrence or metastasis were
found between the two methods [26]. However, the pa-
tients treated with wide resection had poorer functional
outcomes. Gunay et al. performed a retrospective review
of 30 consecutive patients (12 male, 18 female) with a
mean age of 40.7 (range, 16 to 69) years with intramedul-
lary low-grade CS of the long bones treated either by
intralesional curettage or wide resection from 1995 to
2011 [27]. The mean overall follow-up period was 74
(range, 24 to 186) months. There was no difference in the
local recurrence rate between patients treated with intrale-
sional resection and those treated with wide resection.
Intralesional curettage seems to be feasible in selected
cases to reduce the patient’s postoperative morbidity
in cases of grade I CS. The potential for local recurrence
and metastases of low-grade CS is extremely low, with
reported 5-year survival rates ranging from 85% to 100%
following various treatment strategies [19].
Many authors have shown intralesional curettage to be
an acceptable treatment in these cases because it avoids
the morbidity associated with the more radical surgical
procedures without jeopardizing the outcome [3,28-30].
Verdegaal et al. performed a retrospective study to assess
the clinical and oncological outcomes after intralesional
curettage, the application of phenol and ethanol, and
bone grafting in 85 patients treated from 1994 to 2005
[31]. The use of phenol as an adjuvant after intralesional
curettage of low-grade CS of a long bone was safe and
effective, with a recurrence rate of <6% at a mean of
6.8 years after treatment [31]. We did not use adjuvant
phenol and ethanol in the present study. Residual tumors
remained as a result of incomplete curettage, primarily as
a consequence of a bone window that was too small or
had been placed in a suboptimal location.
This study was limited by its observational and retro-
spective design and relatively small number of patients.
We did not use a control group to compare the results.The ideal situation would be to perform a prospective,
multicenter, randomized trial. Another potential limita-
tion is the absence of low-grade CS lesions in the small
tubular bones of the hands and feet in our series. How-
ever, this study supports the view that the combination
of intralesional curettage, high-speed burring, and thermal
cauterization is an effective treatment strategy for low-
grade CS of the long bones, with excellent oncological and
functional results.
Conclusions
In conclusion, the results of intralesional curettage and
cementation for the treatment of low-grade CS showed
that this technique is safe and efficacious. We propose
this treatment option as a rational alternative to more
radical procedures because it preserves function, has low
morbidity, is cost-effective, and does not appear to have
an adverse effect on outcomes.
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